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What is ‘best evidence’?Clinical epidemiologists often claim to use a ‘‘best evi-
dence’’ approach to reach conclusions on what works in
clinical and health care. When should one use a single meg-
astudy (e.g., women’s health initiative), or a combination of
all experimental large and small studies, or the full range of
study designs? Even in this age of acceptance of systematic
reviews, the single megastudy is often viewed as the pre-
ferred evidence. However, as Treadwell et al point out, it
is missing a key principle of the scientific method (namely,
the lack of scientific replication of findings) and the inabil-
ity to determine consistency across studies (e.g., heteroge-
neity of effect sizes). Further, it fails to allow assessment of
generalizability to other types of patients and populations,
may not include a full range of endpoints of interests (such
as work productivity), may also have inadequate statistical
power for the rarer harmful endpoints, and will fail to as-
sess long-term events that occur beyond the time frame
of the study. Hence, there are strong arguments for agreeing
on the approaches based upon a systematic review; but this
itself is complex. Treadwell et al review the pros and cons
of 4 ‘best evidence’ methods.
Carpenter et al present a new model to inform an evolv-
ing framework articulating cancer comparative effective-
ness research data needs. Although randomized controlled
trials remain the gold standard for evaluating intervention
efficacy, they are not always feasible, practical, or timely,
and often do not adequately reflect patient heterogeneity
and real-world clinical practice. On the other hand, compar-
ative effectiveness research can leverage secondary data to
help fill knowledge gaps randomized trials leave unad-
dressed. They discuss elements of contemporary clinical
practice, methodology improvements, and related needs
affecting comparative effectiveness research’s ability to
yield findings clinicians, policy makers, and stakeholders
can confidently act on. Is equivalence the same as non-
inferiority? In another substantive methodologic paper,
Treadwell and colleagues distinguish between equivalence
and non-inferiority and report on the findings of an expert
working group on systematic reviews convened to address
4 areas: 1) unique risk of bias issues for trials self-
identifying as equivalenceenon-inferiority trials; 2) setting
the reviewer’s minimum important difference; 3) analytic
foundations for concluding equivalence or non-inferiority;
and 4) language considerations when concluding equiva-
lence or non inferiority.0895-4356  2012 Elsevier Inc.
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Open access under CC BY-NC-ND license.Appropriateness measurement continues to be difficult to
standardize; Lawson et al review the findings ofmethodologic
studies on the RAND/UCLA (Research and Development/
University of California at Los Angeles) Appropriateness
Method applied to surgical procedures: they studied how it
varies with altering panelist composition or eliminating in-
person discussion between rating rounds.
‘Knowledge translation’ and ‘complex interventions’ are
2 active areas for methodologic innovation; in their paper,
Kastner and Straus successfully integrated two theoretical
frameworks (the Canadian Institutes of Health Research
Knowledge-to-Action and theUKMedical ResearchCouncil
frameworks for complex interventions) in the development
of an osteoporosis clinical decision support tool to inform
the development of a knowledge translation intervention
for the management of osteoporosis. The combined frame-
works can be used to map out the process for translating
evidence into practice by facilitating the rigorous develop-
ment, evaluation, and sustainability of knowledge translation
and complex interventions.
Survival bias is a common concern in statistical analyses
of cohort studies. Stimulated by a study of Oscar actor nom-
inees likelihood of surviving [1],Wolkewitz et al describe ex-
amples and ways of simple graphical display for avoidable
types of bias (because of a time-dependent study entry or
a time-dependent exposure or treatment) applied to several
clinical areas, including cardiology, critical care, endocrinol-
ogy, hepatology, infectious disease, nephrology, neurology,
and obstetrics. Selection bias related to sociodemographic
characteristics have been amply documented, but studies
on selection bias related to mental health studies are scarce,
given the difficulties of getting accurate health-related data
about non-respondents. Vercambre and Gilbert evaluated
health-related differences between respondents and non-
respondents in a mailed epidemiologic survey on mental
health. They found that respondents used more medical ser-
vices than non-respondents (visits to general practitioners,
dentists, and specialists other than psychiatrists), but mainly
for somatic disorders, as they also were prescribed signi-
ficantly fewer psychotropic drugs. They conclude that
response bias may impact estimation quality even in appar-
ently sociodemographically homogeneous populations; they
also showed that adjusting by age and gender can actually in-
crease the error. Health care utilization (HCU) databases are
widespread sources of data for pharmacoepidemiologic
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not measured in such databases. Corrao et al showed how
the impact of confounders in a study could be quantitatively
assessed.
David et al assessed the cost-effectiveness of sample size
maintenance programs in a prospective cohort. They found
that incorporating substitution sampling into a sample size
maintenance program was more cost-effective than the
usual practice of reminders and financial incentives. Van
Breukelen and Candel present simple guidelines for calcu-
lating efficient sample sizes in cluster randomized trials
with unknown intraclass correlation and varying cluster
sizes. They recommend that in calculating a sample size,
researchers must determine the cost per cluster and cost
per person during the study design. They must also report
these costs and the outcome intraclass correlation and var-
iance to improve the planning of future trials.
‘Reverse causality’ is a term proposed to explain the ob-
servation that compensation claims (such as after rear end
car collisions) are associated with a slower recovery, and
that the compensation payment incentivises the claimant
to report a slower recovery. A study by Spearing et alsuggest that this causal interpretation may be the reverse
of the truth (i.e., patients with poor recovery for legitimate
medical or other social reasons are more likely to claim);
they call this incorrect inference ‘reverse causality bias.’
These authors demonstrate a technique for resolving this
problem in observational data.
Feroz et al sought to validate a culturally adapted,
interviewer-administered Bengali SF-36. They found the
Bengali SF-36 to be an acceptable, reliable, and valid
instrument for measuring health-related quality of life in
Bangladeshi patients with rheumatoid arthritis.
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